QL Biopharm Fires China’s First Shot At Monthly GLP-1 Obesity Drug

 
• By Dexter Jie Yan

Without a placebo control arm, ZT002, a once-monthly GLP-1 receptor agonist from the Chinese biotech, reduced body weight by 17.1% from baseline at 30 weeks in Chinese obese patients, data from a Phase Ic clinical study showed.

dosing frequency
A once monthly dosing regimen will play into the advantage of QL Biopharma's ZT002. • Source: Shutterstock

More from China

More from Focus On Asia